216 related articles for article (PubMed ID: 22727640)
21. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
Pierre F; Regan CF; Chevrel MC; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Rice WG; Ryckman DM
Bioorg Med Chem Lett; 2012 May; 22(9):3327-31. PubMed ID: 22460033
[TBL] [Abstract][Full Text] [Related]
22. Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione.
Romagnoli R; Baraldi PG; Salvador MK; Camacho ME; Balzarini J; Bermejo J; Estévez F
Eur J Med Chem; 2013 May; 63():544-57. PubMed ID: 23537942
[TBL] [Abstract][Full Text] [Related]
23. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
24. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
[TBL] [Abstract][Full Text] [Related]
25. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
26. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
[TBL] [Abstract][Full Text] [Related]
27. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, Pim kinase inhibitory potencies and in vitro antiproliferative activities of diversely substituted pyrrolo[2,3-a]carbazoles.
Akué-Gédu R; Nauton L; Théry V; Bain J; Cohen P; Anizon F; Moreau P
Bioorg Med Chem; 2010 Sep; 18(18):6865-73. PubMed ID: 20728368
[TBL] [Abstract][Full Text] [Related]
29. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
Wu B; Wang HL; Cee VJ; Lanman BA; Nixey T; Pettus L; Reed AB; Wurz RP; Guerrero N; Sastri C; Winston J; Lipford JR; Lee MR; Mohr C; Andrews KL; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):775-80. PubMed ID: 25616902
[TBL] [Abstract][Full Text] [Related]
30. Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.
Barberis C; Moorcroft N; Arendt C; Levit M; Moreno-Mazza S; Batchelor J; Mechin I; Majid T
Bioorg Med Chem Lett; 2017 Oct; 27(20):4730-4734. PubMed ID: 28947155
[TBL] [Abstract][Full Text] [Related]
31. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.
Wang T; Block MA; Cowen S; Davies AM; Devereaux E; Gingipalli L; Johannes J; Larsen NA; Su Q; Tucker JA; Whitston D; Wu J; Zhang HJ; Zinda M; Chuaqui C
Bioorg Med Chem Lett; 2012 Mar; 22(5):2063-9. PubMed ID: 22305584
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of 5-(3-(pyrazin-2-yl)benzylidene)thiazolidine-2,4-dione derivatives as pan-pim kinases inhibitors.
Lee J; Park J; Hong VS
Chem Pharm Bull (Tokyo); 2014; 62(9):906-14. PubMed ID: 24954014
[TBL] [Abstract][Full Text] [Related]
34. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
35. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
36. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
[TBL] [Abstract][Full Text] [Related]
37. Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors.
Ni Y; Gopalsamy A; Cole D; Hu Y; Denny R; Ipek M; Liu J; Lee J; Hall JP; Luong M; Telliez JB; Lin LL
Bioorg Med Chem Lett; 2011 Oct; 21(19):5952-6. PubMed ID: 21862328
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.
Medina JR; Grant SW; Axten JM; Miller WH; Donatelli CA; Hardwicke MA; Oleykowski CA; Liao Q; Plant R; Xiang H
Bioorg Med Chem Lett; 2010 Apr; 20(8):2552-5. PubMed ID: 20335034
[TBL] [Abstract][Full Text] [Related]
39. Discovery of benzo[cd]indol-2-one and benzylidene-thiazolidine-2,4-dione as new classes of NLRP3 inflammasome inhibitors via ER-β structure based virtual screening.
Abdullaha M; Ali M; Kour D; Kumar A; Bharate SB
Bioorg Chem; 2020 Jan; 95():103500. PubMed ID: 31869665
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
